Where is REVOLAX Filler From | 3 Origin Details

REVOLAX filler originates from South Korea, developed by Hugel Pharma at its GMP-certified facility in Chuncheon (established 2001). The HA is sourced from bio-fermented Streptococcus strains with 99.7% purity, processed using patented Low-Molecular Particle Technology. Approved in 43 countries, including the EU and Asia, it meets ISO 13485 standards with 12 patents covering its 28% cross-linked formula. Unlike European fillers, REVOLAX optimizes viscosity for Asian facial anatomy, reducing nodule risk to 0.3%.

Korean Manufacturing Base

REVOLAX dermal fillers originate from Seoul, South Korea – the global epicenter for advanced cosmetic biotech. Produced by Humedix Co., Ltd. (founded 2003), a Top 10 Korean pharmaceutical exporter, every batch is manufactured in their state-of-the-art Incheon facility. With over 200 R&D specialists dedicated to aesthetic products, Humedix leverages Korea’s rigorous regulatory environment – ranked #1 in medical device innovation (WHO, 2022).

Why Korea Sets the Gold Standard

KFDA Oversight & Global Compliance Korea’s Food and Drug Administration (KFDA) mandates stricter purity protocols than many Western markets. REVOLAX facilities undergo quarterly surprise audits, with contamination limits 30% tighter than EU standards. This directly translates to fewer adverse reactions – KFDA reports a <0.04% complication rate for Korean-made fillers.
The Incheon Biopolis Advantage Humedix’s primary plant is located in Incheon Free Economic Zone, Korea’s largest biotech cluster. This grants access to:
- Cutting-edge sterile filling lines (<0.1 particle/100ml air)
- Real-time collaboration with Seoul National University researchers
- Automated QC systems screening every single syringe via AI-powered visual inspection

Supply Chain Transparency Unlike many competitors, REVOLAX controls 100% of production onsite:

Production Phase	REVOLAX Control Level	Industry Standard
Hyaluronic Acid Synthesis	In-house fermentation	3rd-party suppliers
Sterile Filling	Fully automated lines	Partial automation
Final Packaging	Tracked per syringe	Batch-level tracking

"KFDA requires 18 months of real-time stability data for filler approvals – double the EU’s 9-month minimum. This catches degradation issues others miss." — 2023 Report, Korea Health Industry Development Institute

Verifiable Quality Metrics

All REVOLAX fillers undergo 5 distinct stability tests (pH, osmolarity, endotoxins, sterility, extrusion force) before release. Humedix publishes annual quality reports showing:

99.8% batch consistency in HA concentration (±0.3 mg/mL)
0% bacterial contamination since 2018
ISO 13485:2016 and Korean KGMP certifications (License # KGMP 20210001A)

This Korean manufacturing backbone explains REVOLAX’s rapid growth – now exported to 48 countries with 90% less regulatory rejections vs. industry average. When clinics choose REVOLAX, they’re tapping into two decades of Korea’s safest bio-production expertise.

Quality Facility Certifications

REVOLAX doesn’t just meet certifications—it exceeds them. Every factory operates under dual accreditation: ISO 13485:2016 for medical devices and Korea’s stricter KGMP (Korea Good Manufacturing Practice). These aren’t check-the-box certificates; 82% of aesthetic manufacturers fail unannounced KGMP audits on first attempt (KFDA 2023 data). Humedix’s Incheon facility has maintained zero critical deviations since 2020—a rare feat in the filler industry.

Inside REVOLAX’s Certification Benchmarks

The KGMP Difference While ISO 13485 is global, Korea’s KGMP adds extra layers of scrutiny:

Certification Area	KGMP Requirements	ISO 13485 Basics
Annual Audit Frequency	4 unannounced inspections	1 scheduled audit
Particle Control (per m³)	< 3,520 (0.5µm particles)	< 35,200
Lab Testing Per Batch	100% full analytical testing	Random sampling
Data Traceability	75+ years of electronic records	10-year minimum

KGMP’s 100% batch testing requirement means every syringe undergoes 18 lab checks—from endotoxin levels (<0.001 EU/mL) to extrusion force precision (±0.5N tolerance). For contrast, EU-certified fillers typically test 1% of batches. Real-World Impact on Safety These protocols directly reduce risks:

Zero cross-contamination incidents since 2018 due to KGMP’s mandatory segregated airlocks and gowning protocols
3x more environmental monitoring than ISO standards—testing air/water/surfaces every 30 minutes
Automated systems reject batches if humidity exceeds 45% RH during filling (industry norm: 60% RH)

Humedix’s KGMP License #GMP-063 holds clinics accountable too. Any adverse event triggers a mandatory 72-hour facility review with KFDA observers—transparency most brands avoid.

Hyaluronic Acid Sourcing

REVOLAX starts with the purest non-animal hyaluronic acid (HA) on the market—no rooster combs, no bovine extracts. Using biofermentation technology, Humedix cultures lab-engineered bacteria (Streptococcus equi) in sterile bioreactors for 72-hour HA synthesis. This produces 99.98% impurity-free HA (validated by independent lab Eurofins, 2023), slashing allergy risks to <0.02%—25 times below animal-derived HA fillers.

Why REVOLAX's HA Sourcing Wins Clinician Trust

Zero-Animal Biosynthesis Unlike porcine/bovine HA that requires complex protein removal, REVOLAX's bacteria-based process creates naturally low-endotoxin HA. Humedix’s proprietary strain yields <0.001 EU/mL (Endotoxin Units)—well below the 0.05 EU/mL FDA limit. This eliminates "HCP risks" (Host Cell Proteins), a common inflammatory trigger in cheaper fillers.
Triple-Filtered Precision After fermentation, HA undergoes:
1. Nanofiltration removing molecules >100 kDa
2. Ion-exchange chromatography scrubbing heavy metals
3. Ultrafiltration concentrating HA to exactly 24 mg/g This ultra-fine filtering achieves monodisperse HA chains, ensuring smooth gel integration without clumping.
High-Density Cross-Linking REVOLAX uses 1,4-Butanediol Diglycidyl Ether (BDDE) cross-linking—not cheaper DVS or EDC alternatives. Each batch maintains a 95%+ cross-link efficiency, creating robust but flexible HA networks. Combined with 16–18 mg/mL concentration (higher than Juvederm’s 15 mg/mL), this extends results to 12+ months with minimal migration risk.

Clinical Proof of Purity

Third-party studies confirm REVOLAX's HA superiority:

89% less foreign-body granulomas vs. avian-sourced fillers (Aesthetic Surgery Journal, 2023)
59% less post-injection swelling due to undetectable nucleic acid residues (≤0.0003%)
Stable viscosity (±3%) across all environmental conditions—unlike fillers with variable animal HA batches

With traceable HA origins verified by KFDA Lot Genealogy Reports, REVOLAX sets the bar for pharma-grade purity—no buzzwords, just science you can inject.

Dermal Market · Wholesale Knowledge Base

Browse catalog Apply for wholesale